ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1553

Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

Philip J. Mease1, Roy Fleischmann2, Owen Davies3, Tommi Nurminen4 and Désirée van der Heijde5, 1Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, 2Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim, Germany, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, certolizumab pegol, Clinical research, Psoriatic arthritis and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However, to date there is a shortage of data regarding early identification of non-responders in psoriatic arthritis (PsA). Such analyses may help avoid unnecessary exposure, increase cost-effectiveness and improve the chance of achieving long-term treatment goals. Here we aim to assess the association between disease activity (DA) and clinical response (CR) during the first 12 weeks (wks) of treatment, and attainment/lack of attainment of treatment targets at Wk48 in PsA patients (pts) receiving certolizumab pegol (CZP).

Methods: The relationship between DA state during the first 12 wks of treatment, and Minimal Disease Activity (minDA)3 or DAS28(CRP) <2.6 at Wk48 was assessed post hoc using data from the RAPID-PsA study (NCT01087788).4 DA state was defined using either DAS28(CRP) values: <2.6, 2.6–3.2, 3.2–5.1, >5.1; or PsARC response/non-response. Descriptive analyses are based on all pts randomized to CZP from Wk0. Pts that discontinued treatment during the first 12 wks were excluded from the analysis. For remaining pts, missing data were imputed using LOCF for DAS28 and PsARC, and NRI for minDA.

Results: A relationship between Wk2 DA state and Wk48 minDA was observed, with 68% (17/25) of pts with DAS28(CRP) <2.6 at Wk2 achieving Wk48 minDA, compared with 10% (5/52) of pts with Wk2 DAS28(CRP) >5.1. This trend was maintained at Wk12, by which point more pts had lower DA. 73% (57/78) of pts with Wk12 DAS28(CRP) <2.6 achieved Wk48 minDA, compared to 0% (0/26) of pts with Wk12 DAS28(CRP) >5.1 (Table A). When Wk48 DAS28(CRP) <2.6 – a less stringent target that excludes enthesitis and skin manifestations – was used, a similar trend was observed, but more pts in each category achieved the target; however, still only 4% (1/26) of pts with Wk12 DAS28(CRP) >5.1 attained Wk48 DAS28(CRP) <2.6 (Table B). CR at Wk12 was also associated with likelihood of attaining minDA at Wk48: Of 153/256 (60%) CZP pts that achieved Wk12 DAS28(CRP) CR >1.2, 50% (76/153) achieved Wk48 minDA, compared to 32% (17/53) of pts with Wk12 DAS28(CRP) CR 0.6–1.2 and 12% (6/50) of Wk12 non-responders (DAS28[CRP] CR ≤0.6). PsARC response at Wk12 was also associated with Wk48 outcomes: 10.7% (6/56) of Wk12 PsARC non-responders achieved Wk48 minDA, compared to 47.7% (95/199) of Wk12 PsARC responders.

Conclusion: Using DA state and CR level at an early stage of CZP treatment, it was possible to identify PsA pts unlikely to achieve long-term treatment goals. This approach may enable physicians adopting a treat-to-target strategy to determine early on when to change therapy in pts not responding to CZP.

References:

1. van der Heijde D. J Rheum 2012;39(7):1326–1333

2. Zhu B. Br J Dermatol 2013;169(6):1337–1341

3. Coates L.C. Ann Rheum 2010;69(1):48–53

4. Mease P.J. Ann Rheum Dis 2014;73(1):48–55

 


Disclosure:

P. J. Mease,

Abbott, AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex,

2;

R. Fleischmann,

Genetech Inc, Roche, Abbott, Amgen, UCB Pharma, Pfizer, BMS, Lilly, Sanofi-Aventis, MSD, Novartis, BiogenIdec, Astellas, AstraZeneca, Janssen,

2,

Roche, Abbott, Amgen, UCB Pharma, Pfizer, BMS, Lilly, Sanofi-Aventis, Novartis, Astellas, AstraZeneca, Janssen,

5;

O. Davies,

UCB Pharma,

3,

UCB Pharma,

1;

T. Nurminen,

UCB Pharma,

3;

D. van der Heijde,

AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Vertex,

5,

Imaging Rheumatology bv,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-and-clinical-response-early-in-the-course-of-treatment-predict-long-term-outcomes-in-psoriatic-arthritis-patients-treated-with-certolizumab-pegol/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology